No Data
Lipella Pharmaceuticals Has Completed Dosing For The First Cohort In Its Phase 2A Trial Of LP-310, A Liposomal-tacrolimus Oral Rinse Being Developed For Oral Lichen Planus, Topline Data Is Expected By Year-end And Complete The Trial By Mid-2025
Express News | Lipella Pharmaceuticals Inc - Trial Expected to Conclude by Mid-2025 With Top-Line Data by Year-End 2024
Express News | Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating
Maxim Group Keeps Their Buy Rating on Lipella Pharmaceuticals, Inc. (LIPO)
Express News | Lipella Pharmaceuticals Inc : Maxim Group Cuts Target Price to $10 From $16
No Data
No Data